DeutschNewstral
Article
bizjournals.com on 2021-09-15 23:07
Seattle biotech Alpine Immune Sciences raises $91M for drug development
Related news
- Former Dendreon CEO's new biotech Alpine Immune Sciences raises $1.3Mbizjournals.com
- Drug giant Merck acquires Seattle biotech Immune Design for $300 millionbizjournals.com
Alpine pulls in $48 million; tops for a local biotech this yearseattletimes.com- Boulder biotech acquires Seattle companybizjournals.com
- Maryland company to spin out new publicly traded Seattle cancer biotechbizjournals.com
- Seattle biotech expands portfolio with Boston acquisitionbizjournals.com
- Seattle biotech Oncothyreon names new CEObizjournals.com
- Seattle biotech outpaces Washington's public companiesbizjournals.com
- Seattle biotech PhaseRx files to go publicseattletimes.com
- Seattle Genetics buys biotech factory in Bothellseattletimes.com
- Former Zillow CFO heads to Seattle biotechbizjournals.com
- Seattle biotech Silverback Therapeutics prices upsized IPOseattletimes.com
- Seattle biotech Faraday Pharmaceuticals names new CEObizjournals.com
- Seattle biotech Adaptive buys San Francisco firmseattletimes.com
- Seattle Genetics operations chief resigns to lead stealthy Seattle biotechbizjournals.com
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024Star Tribune- IVertex may have to pay more than $65 for Alpine Immune stock ($ALPN)invezz.com
Adaptive Biotech Gets $195M to Dig Deep Into The Immune System's SecretsForbes- Seattle fire hazmat investigates odor at UW health-sciences buildingseattletimes.com